BBOT Unveils Promising Clinical Data for RAS and PI3Kα Pipeline Programs
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 – BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT) has announced encouraging preliminary safety and efficacy data from its innovative pipeline targeting RAS-pathway malignancies. The updates include findings from three key programs: BBO-8520, BBO-11818, and BBO-10203.
Overview of Clinical Findings
BBOT's recent clinical updates showcase significant advancements for patients battling non-small cell lung cancer (NSCLC) and other cancers caused by RAS mutations. Among the findings, BBO-8520 demonstrated a **65% objective response rate (ORR)** in NSCLC patients with the KRASG12C mutation. The 6-month progression-free survival (PFS) rate was recorded at **66%**, with an impressive **83%** of patients remaining on treatment for at least six months.
The prominent results indicate that all five initial patients with KRASG12C and STK11 and/or KEAP1 co-mutations obtained a partial response, reinforcing BBO-8520's potential as a leading treatment option.
Pipeline Program Highlights
- BBO-8520: This direct inhibitor targeting KRASG12C has shown a promising safety profile when used as a monotherapy and in combination with pembrolizumab.
- BBO-11818: Observed notable anti-tumor activity in pancreatic cancer patients, with confirmed partial responses and reduced tumors across varying dose levels.
- BBO-10203: Highlighted for its differentiated safety profile, this therapy showed no instances of hyperglycemia, regardless of baseline HbA1c and glucose levels.
Expert Commentary
Eli Wallace, PhD, CEO of BBOT, emphasized the strength of their precision oncology portfolio, stating, “By focusing on ON biology and leveraging strong chemistry, we are developing highly selective therapies designed to be better tolerated and deliver greater anti-tumor activity.” This indicates BBOT’s commitment to innovative cancer treatments.
Furthermore, Dr. Yong (Ben) Ben, Chief Medical and Development Officer at BBOT, noted the favorable benefit-risk profile of BBO-8520 and its potential to serve as a critical front-line partner in combination therapy with pembrolizumab.
Upcoming Developments
BBOT plans to deliver additional data updates regarding the efficacy and safety results of BBO-8520 in combination with pembrolizumab in the latter half of **2026**. Further combination studies with BBO-10203 are also anticipated to commence within the same year.
Conclusion
As BBOT continues to reveal promising data across its RAS and PI3Kα pipeline programs, investors and stakeholders can look forward to further developments that could reshape treatment paradigms for aggressive cancers. The company's ongoing research and patient-centric approach position BBOT favorably within the evolving oncology landscape.